Company Overview
- Website
- alkeuspharma.com
- Phone
- (800) 287-2755
- Employees
- 1
- Founded in
- 2010
- Industry
- BioTech/Drugs
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing32541 - Pharmaceutical and Medicine Manufacturing
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs
Financials & Stats
Revenue
$5B
Recent News & Media
Alkeus Pharmaceuticals Presents Gildeuretinol Data During
- May 7, 2025
- globenewswire.com
Alkeus Pharmaceuticals Announces Presentations of Gildeuretinol Data During the Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
- Apr 24, 2025
- globenewswire.com
Alkeus Pharmaceuticals Announces Two Presentations of Oral Gildeuretinol Data During the 48th Annual Meeting of the Macula Society Being Held February 12-15, 2025
- Feb 11, 2025
- globenewswire.com
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
- Jan 9, 2025
- biospace.com
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 7, 2025
- globenewswire.com
Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
- Dec 5, 2024
- firstwordpharma.com
Who is Alkeus Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts. The company employs 1 person and reports $5.4 million in annual revenue. Alkeus Pharmaceuticals focuses on developing transformative therapeutics for serious, progressive eye diseases that can lead to blindness. Their lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD. This compound has demonstrated statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial, leading to Breakthrough Therapy Designation for the treatment of Stargardt Disease. For more information about Alkeus Pharmaceuticals Inc., please visit their website at alkeuspharma.com.
Company Leadership
Alkeus Pharmaceuticals Inc Tech Stack
Companies Similar to Alkeus Pharmaceuticals Inc
Analyze industry trends and opportunities by examining competitors and companies comparable to Alkeus Pharmaceuticals Inc, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 5M | 5 | Boston, MA | ||
| 5M | 80 | New York, NY | 2003 | |
| 5M | 56 | Phoenix, AZ |